Summit Therapeutics PLC Company Profile (NASDAQ:SMMT)

About Summit Therapeutics PLC

Summit Therapeutics PLC logoSummit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company's lead DMD product candidate is SMT C1100, an orally administered small molecule. The Company's lead CDI product candidate is SMT19969, an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics, Inc., Summit (Oxford) Limited, Summit (Wales) Limited and MuOx Limited, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SMMT
  • CUSIP:
Key Metrics:
  • Previous Close: $10.02
  • 50 Day Moving Average: $6.84
  • 200 Day Moving Average: $7.52
  • 52-Week Range: $4.26 - $12.78
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.26
  • P/E Growth: 0.00
  • Market Cap: $123.19M
  • Outstanding Shares: 12,294,000
  • Beta: 0.91
Additional Links:
Companies Related to Summit Therapeutics PLC:

Analyst Ratings

Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.50 (124.55% upside)

Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
DateFirmActionRatingPrice TargetDetails
9/16/2016HC WainwrightInitiated CoverageBuy$26.00View Rating Details
9/9/2016Canaccord GenuityReiterated RatingBuy$14.00View Rating Details
6/21/2016Janney Montgomery ScottInitiated CoverageBuyView Rating Details
6/16/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
10/2/2015Needham & Company LLCReiterated RatingBuy$22.00View Rating Details
4/2/2015JMP SecuritiesInitiated CoverageOutperform$32.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Summit Therapeutics PLC (NASDAQ:SMMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/27/2015Q215($0.06)($0.55)ViewListenView Earnings Details
6/11/2015Q115($0.06)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Summit Therapeutics PLC (NASDAQ:SMMT)
Current Year EPS Consensus Estimate: $-2.14 EPS
Next Year EPS Consensus Estimate: $-3.07 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.78)($0.78)($0.78)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Summit Therapeutics PLC (NASDAQ:SMMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Summit Therapeutics PLC (NASDAQ:SMMT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Summit Therapeutics PLC (NASDAQ:SMMT)
DateHeadline
streetinsider.com logoUnusual 11 Mid-Day Movers 9/26: (ARRY) (SMMT) (ACTA) Higher; (PTIE) (DRRX) (SALE) Lower - StreetInsider.com (NASDAQ:SMMT)
www.streetinsider.com - September 26 at 7:24 PM
News IconStock Noted Gapping Up Pre-Market: Summit Therapeutics plc (:SMMT) - Post News (NASDAQ:SMMT)
www.kentuckypostnews.com - September 26 at 7:24 PM
schaeffersresearch.com logoBiotech Buzz: Axovant Sciences Ltd, Summit Therapeutics PLC (ADR), and Mylan NV - Schaeffers Research (blog) (NASDAQ:SMMT)
www.schaeffersresearch.com - September 26 at 7:24 PM
streetinsider.com logoSummit Therapeutics (SMMT) Receives FDA Fast Track Status for DMD Treatment - StreetInsider.com (NASDAQ:SMMT)
www.streetinsider.com - September 26 at 7:24 PM
globenewswire.com logoSummit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy (NASDAQ:SMMT)
globenewswire.com - September 26 at 10:03 AM
4-traders.com logoSummit Therapeutics : Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD (NASDAQ:SMMT)
www.4-traders.com - September 26 at 10:03 AM
seekingalpha.com logoSummit's ezutromid Fast Track'd for Duchenne muscular dystrophy (NASDAQ:SMMT)
seekingalpha.com - September 26 at 10:03 AM
investors.com logoSummit Therapeutics' DMD treatment granted US fast track status (NASDAQ:SMMT)
www.proactiveinvestors.com - September 26 at 10:03 AM
publicnow.com logoSummit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD (NASDAQ:SMMT)
www.publicnow.com - September 26 at 10:03 AM
News IconBased Eldorado Resorts buying Isle of Capri Casinos (NASDAQ:SMMT)
myhealthbowl.com - September 24 at 6:36 PM
kcregister.com logoTrader's Watch List: Summit Therapeutics plc (NASDAQ:SMMT), VimpelCom Ltd. (NASDAQ:VIP), Amicus Therapeutics ... - KC Register (NASDAQ:SMMT)
www.kcregister.com - September 23 at 12:01 PM
News IconStock Intraday Alert - Summit Therapeutics plc's (SMMT) - Hot Stocks Point (NASDAQ:SMMT)
www.hotstockspoint.com - September 22 at 12:11 PM
finance.yahoo.com logoCoverage initiated on Summit Therapeutics by H.C. Wainwright (NASDAQ:SMMT)
finance.yahoo.com - September 16 at 10:54 AM
nasdaq.com logoSummit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community - Nasdaq (NASDAQ:SMMT)
www.nasdaq.com - September 12 at 6:54 PM
capitalcube.com logoSummit Therapeutics Plc :SMMT-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2016 (NASDAQ:SMMT)
www.capitalcube.com - September 12 at 12:05 PM
nasdaq.com logoPre-Market Earnings Report for September 8, 2016 : DCI, SAIC, DSGX, NAV, BKS, SNOW, CONN, SMMT, SKIS - Nasdaq (NASDAQ:SMMT)
www.nasdaq.com - September 8 at 11:13 AM
investors.com logoSummit Therapeutics highlights clinical progress - Proactive Investors USA & Canada (NASDAQ:SMMT)
www.proactiveinvestors.com - September 8 at 11:13 AM
finance.yahoo.com logoSummit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational Progress (NASDAQ:SMMT)
finance.yahoo.com - September 8 at 11:13 AM
publicnow.com logoFinancial Results for the Second Quarter Ended 31 July 2016 (NASDAQ:SMMT)
www.publicnow.com - September 8 at 11:13 AM
News IconSummit Therapeutics to Present at 18th Annual Rodman Renshaw Global Investment Conference - EconoTimes (NASDAQ:SMMT)
www.econotimes.com - September 7 at 11:05 AM
finance.yahoo.com logoSummit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference (NASDAQ:SMMT)
finance.yahoo.com - September 7 at 11:05 AM
benzinga.com logoSummit Therapeutics to Report Financial Results... (NASDAQ:SMMT)
www.benzinga.com - September 6 at 7:31 PM
globenewswire.com logoSummit Therapeutics plc : Notice of Results (NASDAQ:SMMT)
inpublic.globenewswire.com - September 6 at 7:31 PM
investingnews.com logoSummit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016 - Investing News Network (press release) (registration) (blog) (NASDAQ:SMMT)
investingnews.com - September 6 at 12:05 PM
einnews.com logoSummit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016 - EIN News (press release) (NASDAQ:SMMT)
www.einnews.com - September 5 at 11:26 AM
investors.com logoSummit to include new DMD formulation in PhaseOut trial - Proactive Investors USA & Canada (NASDAQ:SMMT)
www.proactiveinvestors.com - August 9 at 7:47 PM
trustnet.com logoSummit Reports Positive Phase 1 Data and Outlin... (NASDAQ:SMMT)
www.trustnet.com - August 9 at 10:44 AM
finance.yahoo.com logoSummit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid (NASDAQ:SMMT)
finance.yahoo.com - August 9 at 10:44 AM
finance.yahoo.com logo7:04 am Summit Therapeutics reports Phase 1 clinical trial results that show a new formulation of ezutromid 'achieved a greater than six-fold increase in maximum plasma levels in DMD patients ' (NASDAQ:SMMT)
finance.yahoo.com - August 9 at 10:44 AM
publicnow.com logoPositive Phase 1 Data and Outlined Route to Market Strategy for Ezutromid (NASDAQ:SMMT)
www.publicnow.com - August 9 at 10:44 AM
globenewswire.com logoSummit Therapeutics to Present at Canaccord Genuity Growth Conference - GlobeNewswire (press release) (NASDAQ:SMMT)
www.globenewswire.com - August 6 at 10:08 AM
nasdaq.com logoSummit Therapeutics to Present at Canaccord Genuity Growth Conference - Nasdaq (NASDAQ:SMMT)
www.nasdaq.com - August 5 at 7:41 PM
finance.yahoo.com logoSummit Therapeutics to Present at Canaccord Genuity Growth Conference (NASDAQ:SMMT)
finance.yahoo.com - August 5 at 10:32 AM
ftsenews.co.uk logoNew Broker Ratings For Summit Therapeutics Plc (SMMT) - FTSE News (NASDAQ:SMMT)
www.ftsenews.co.uk - July 26 at 7:53 PM
News IconWere Analysts Bullish Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) This Week? - Consumer Eagle (NASDAQ:SMMT)
www.consumereagle.com - July 22 at 7:16 PM
News IconSummit Therapeutics plc : Result of AGM - PharmiWeb.com (press release) (NASDAQ:SMMT)
www.pharmiweb.com - July 19 at 8:12 AM
globenewswire.com logoSummit Therapeutics plc : Result of AGM (NASDAQ:SMMT)
inpublic.globenewswire.com - July 18 at 12:50 PM
ftsenews.co.uk logoSummit Therapeutics Plc (SMMT) Updated Price Targets - FTSE News (NASDAQ:SMMT)
www.ftsenews.co.uk - July 15 at 12:43 PM
News IconHow Analysts Rated Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) Last Week? - Consumer Eagle (NASDAQ:SMMT)
www.consumereagle.com - July 13 at 10:21 AM
News IconBullish Chart Formation for Summit Therapeutics PLC (ADR) After Forming Inverse H&S Chart Pattern - Press Telegraph (NASDAQ:SMMT)
presstelegraph.com - July 11 at 12:05 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For Summit Therapeutics Plc (SMMT) - Fiscal Standard (NASDAQ:SMMT)
www.fiscalstandard.com - July 11 at 12:05 PM
fiscalstandard.com logoBroker Outlook For The Week Ahead Summit Therapeutics Plc (SMMT) - Fiscal Standard (NASDAQ:SMMT)
www.fiscalstandard.com - July 6 at 12:06 PM
News IconUK car production up in May, but stability vital, says SMMT - Plastics & Rubber Weekly (NASDAQ:SMMT)
www.prw.com - July 2 at 10:05 AM
News IconSingle market boosts UK car industry (NASDAQ:SMMT)
www.thedailystar.net - July 1 at 7:29 PM
News IconBrexit vote to lead to 'instability' in the car industry (NASDAQ:SMMT)
www.bbc.com - July 1 at 7:29 PM
News IconSingle market boosts United Kingdom auto industry, says SMMT (NASDAQ:SMMT)
newsinfilm.com - July 1 at 7:29 PM
News IconUK car output rises 26% in May, but industry group sees Brexit threat (NASDAQ:SMMT)
europe.autonews.com - July 1 at 7:29 PM
News IconUK automotive reports record £71.6 billion turnover (NASDAQ:SMMT)
www.materialstoday.com - July 1 at 7:29 PM
News IconU.K. Auto Industry’s 2015 Growth Robust, Report Says (NASDAQ:SMMT)
wardsauto.com - July 1 at 7:29 PM
News IconUK car production up in May, but stability vital, says SMMT (NASDAQ:SMMT)
www.prw.com - July 1 at 7:29 PM

Social

Summit Therapeutics PLC (NASDAQ:SMMT) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff